Innovation. Experience. Results.
Home | 
About Us | 
Contact Us | 
Glossary | 

The Process

Clinical Trials and Research

Bruckner Oncology is proud to be affiliated with the Clinical Research Alliance, a best-in-class, global team of physicians and medical professionals committed to advancing clinical research in Oncology.
In addition to our standard and innovative cancer treatment offerings, we are also a bridge to providing clinical trial opportunities to patients who are interested and qualify across a range of specific areas. We are a qualified clinical site for over 30 trials across a range of cancers including:
  • Breast cancer
  • Gastric cancer
  • Metastatic colorectal cancer (MCRC)
  • Multiple myeloma
  • Non-small cell lung cancer (NSCLC)
  • Ovarian cancer
  • Pancreatic
  • Renal cancer
Below is a list of clinical trials we are currently offering. New trials are being added on a monthly basis. Please contact us to learn more about these clinical trial opportunities.


Phase II-III clinical trial which adds Vitamin C to chemotherapy "core" regimens (GFLIO and GFLIO-D)  for patients with locally advanced and metastatic pancreatic cancer (APC)

Phase III Randomized Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in 1st Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma 

Clovis CO-101-001 
Phase II Open-Label, Multicenter Study Comparing CO-1.01 with Gemcitabine as 1st Line treatment in Metastatic Pancreatic Adenocarcinoma 

GSK MEK113487
Phase II Placebo-Controlled, Trial of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in 1st Line treatment of Metastatic Pancreatic Adenocarcinoma

Peregrine PPHM 1002 
Phase II Open Label, Trial of Gemcitabine With or Without Bavituximab in 1st Line treatment of Metastatic Pancreatic Adenocarcinoma

Phase 2b Randomized, Dose Escalation study of the Safety and Exploratory Efficacy of Kanglaite Injection plus Gemcitabine (G+K) vs. Gemcitabine in the 1st Line Treatment of Patients with Advanced Pancreatic Cancer

Breast Cancer

1st Line Treatment in HER-2 positive MBC
Roche BO22589/TDM4788g
Phase III, Study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab vs T-DM1 (blinded for pertuzumab), vs trastuzumab plus taxane, as 1st Line Treatment in HER-2 positive MBC

1st Line Her 2 Neu negative MBC
Novartis CZOL446EUS147 Z -ACT 1
Phase IV, Open-label, Study of the anti-cancer effects of zoledronic acid in combination with Chemotherapy +/- Avastin or Hormonal Therapy using circulating tumor cell measurements (CTCs) in the 1st Line and 2nd Line Treatment of patients with HER2-negative MBC without bone metastases

1st - 4th Line HER-2 positive MBC
NEW Incyte INCB7839-204
A Phase I/II, study to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine metastatic HER2+ MBC

2nd line Her -2 positive Locally Advanced or MBC
Novartis CRAD001W2301
Phase III, Double-Blind, Placebo-Controlled Study of daily Everolimus in Combination with Trastuzumab and Vinorelbine in Pretreated Women with HER2/neu Over-expressing Locally Advanced or Metastatic Breast Cancer

3rd-6th Line MBC
Celldex CDX011-03
Phase II, Open Label, Study of CDX-011 vs Investigator Choice Chemotherapy in the 3rd-6th Line Treatment of patients with GPNMB-expressing MBC

Novartis CZOL446E2352 Optimize 2
Phase III, Double-Blind, Study of the continued efficacy and safety of Zometa® (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from breast cancer

Johnson & Johnson EPO-ANE-3010
Phase 3, Open-Label Study, of Epoetin Alfa plus Standard Supportive Care vs Standard Supportive Care in Anemic Patients with MBC Receiving Standard Chemotherapy

Bayer BAY43-9006/12444
Phase III Double blind Trial of Capecitabine plus Sorafenib vs. Capecitabine plus Placebo in the 1st or 2nd Line Treatment of Locally Advanced or Stage IV Her 2 negative Breast cancer


Novartis AUY922A2202
Phase II randomized, open-label Study of AUY922 vs docetaxel or irinotecan in the 2nd Line treatment of patients with advanced gastric cancer adenocarcinoma or Gastroesophageal junction adenocarcinoma


Genentech MAVERICC ML 25710
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Vs. Bevacizumab/Folfiri with Biomarker Stratification in patients with Previously Untreated Metastatic Colorectal Cancer

Keryx Perifosine 343
A Phase III Randomized Double-Blind Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine vs Placebo Plus Capecitabine in patients who have received multiple prior lines of chemotherapy for Refractory Advanced MCRC

Daiichi ARQ 197-A-U252
Phase 1/2 Trial of Placebo-Controlled, ARQ 197 in Combination with Irinotecan and Cetuximab in the TreatmentSubjects with Metastatic Colorectal Cancer with Wild-Type KRAS Who Have Received Front-Line Systemic Therapy.

Multiple Myeloma

Keryx Perifosine 339
Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib

Celgene Connect MM
The Multiple Myeloma Disease Registry


New Cell Therapeutics PIX306
Phase II randomized, Single-Blind study of Pixantrone + Rituximab vs. Gemcitabine + Rituximab in the treatment of patients with Aggressive B-cell Non-Hodgkins Lymphoma who have relapsed after CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
Polycythemia Vera

Incyte INCB 18424-356
A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Polycythemia Vera Who Are Resistant or Intolerant to Hydroxyurea


Boehringer Ingelheim BIPI1199.14
Phase III study of oral BIBF 1120 plus standard pemetrexed vs placebo plus standard pemetrexed in the 2nd Line Treatment of stage IIIB/IV NSCLC


Morphotek MORAb-003-004PS
Phase III Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse

Morphotek MORAb-003-003PR
Phase III Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer


Pending Trials


Genentech GDC4950g
Phase II Double blind Trial of GDC-0941 or GDC-0980 with Fulvestrant vs. Fulvestrant in the 2nd Line Treatment of Endocrine positive Advanced Breast cancer

Novartis BEZ235B2201
Phase II Trial of orally BEZ235 monotherapy in the 3rd-4th Line Treatment of hormone receptor positive, HER2 negative, MBC, with or without PI3K activated pathway

Roche-Genentech BO25734/TDM4997g
Phase II Open Label Trial of Trastuzumab Emtansine (T-DM1) vs. Physicians Choice in the 3rd Line Treatment of HER2-Positive MBC


BMS 078/306
Phase III, randomized, double-blind study comparing paclitaxel and carboplatin in combination with ipilimumab vs paclitaxel and carboplatin in combination with placebo 1st Line Stage IV or recurrent NSCLC with squamous cell histology only


Phase II, Open-Label, Study to Evaluate the Antitumor Efficacy of CO-1.01 in 2nd Line Treatment of Gemcitabine- Refractory Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression


Immatics IMA 901
Phase III, randomized, study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as 1st Line treatment for advanced/metastatic renal cell carcinoma

Multiple Myeloma

Amgen 20090482 PI: Dr. Coleman
Phase III, randomized, double-blind study of Denosumab Compared with Zoledronic Acid in the treatment of bone disease in subjects with newly diagnosed Multiple Myeloma